LBRX LB Pharmaceuticals Inc - Common Stock
$27.83
价格 · 五月 20, 2026
截至...的财报数据 五月 12, 2026
52周区间
$13–$33
72% of range
分析师评级
BUY
12 analysts
目标价
$44
+58% upside
P/E (TTM)
-7.1
ROE
-25.5%
净利润率
—
LBRX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$27.83
市值
$563M
P/E (TTM)
-7.1
每股收益 (TTM)
$-3.13
营收 (TTM)
—
股息收益率
—
ROE
-25.5%
负债/权益
—
52周区间
$13 – $33
LBRX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
—
EPS
$-3.13
2024-12-31
→
2025-12-31
自由现金流
$-35M
2025-12-31
→
2025-12-31
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
LBRX
同行中位数
P/E (TTM)
-7.1
116.0
P/B (市净率)
1.9
4.0
Price / FCF (股价/自由现金流)
-16.0
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
LBRX
同行中位数
ROA
-14.5%
-3.0%
ROE
-25.5%
-18.9%
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
LBRX
同行中位数
Current Ratio (流动比率)
41.4
2.5
Quick Ratio (速动比率)
39.7
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
LBRX
同行中位数
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
LBRX
同行中位数
LBRX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
12 位分析师
- 强烈买入 4 33.3%
- 买入 7 58.3%
- 持有 1 8.3%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
6 位分析师 · 2026-05-15
中位数
$38.00
平均值
$44.00
← 低于所有目标
$27.83
最低
$31.00
最高
$78.00
中位数目标
$38.00
+36.5%
平均目标
$44.00
+58.1%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.02%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年3月31日 | $-0.67 | $-0.76 | 0.09% |
| 2025年12月31日 | $-0.45 | $-0.46 | 0.01% |
| 2025年9月30日 | $-0.61 | $-0.46 | -0.15% |
同行比较 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| LBRX | $563M | -7.1 | — | — | -25.5% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | — |
| ESPR | — | -33.6 | 21.3% | -5.6% | 6.2% | — |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| RLMD | $354M | -3.3 | 93.7% | — | -112.0% | — |
| SGP | — | — | — | — | 50.0% | — |
| BIOA | $495M | -5.9 | — | -896.1% | -28.4% | — |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 13
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | $17M | $51M | |
| SG&A Expense | $14M | $14M | |
| Operating Expenses | $30M | $65M | |
| Interest Income | $4M | $2M | |
| Other Non-op | $5M | $2M | |
| Pretax Income | $-25M | $-63M | |
| Income Tax | $1.0K | $1.0K | |
| Net Income | $-25M | $-63M | |
| EPS (Basic) | $-3.13 | $-176.15 | |
| EPS (Diluted) | $-3.13 | $-176.15 | |
| Shares (Basic) | 8,045,145 | 358,229 | |
| Shares (Diluted) | 8,045,145 | 358,229 | |
| EBITDA | $321.0K | · |
资产负债表 19
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $250M | $23M | |
| Short-term Investments | $45M | $5M | |
| Prepaid Expense | $13M | $880.0K | |
| Current Assets | $308M | $29M | |
| PP&E (Net) | $2M | $2M | |
| PP&E (Gross) | $2M | $2M | |
| Accum. Depreciation | $420.0K | $101.0K | |
| Total Assets | $313M | $34M | |
| Accounts Payable | $2M | $2M | |
| Accrued Liabilities | $5M | $5M | |
| Current Liabilities | $7M | $8M | |
| Capital Leases | $3M | $3M | |
| Total Liabilities | $12M | $14M | |
| Common Stock | $3.0K | $1.0K | |
| Retained Earnings | $-130M | $-104M | |
| AOCI | $168.0K | $111.0K | |
| Stockholders' Equity | $301M | $-95M | |
| Liabilities + Equity | $313M | $34M | |
| Shares Outstanding | 25,299,372 | 251,655 |
现金流 10
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| D&A | $321.0K | $91.0K | |
| Stock-based Comp | $4M | $3M | |
| Deferred Tax | $0 | $0 | |
| Other Non-cash | $-15M | · | |
| Operating Cash Flow | $-35M | $-53M | |
| CapEx | $52.0K | $769.0K | |
| Investing Cash Flow | $-40M | $23M | |
| Financing Cash Flow | $303M | $38M | |
| Net Change in Cash | $227M | $8M | |
| Free Cash Flow | $-35M | · |
盈利能力 2
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| ROA | -14.5% | · | |
| ROE | -25.5% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 41.4 | · | |
| Quick Ratio | 39.7 | · |
估值 (TTM) 8
| 指标 | 趋势 | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-25M | · | |
| Market Cap | $563M | · | |
| P/E | -7.1 | · | |
| P/B | 1.9 | · | |
| P / Tangible Book | 1.9 | · | |
| P / Cash Flow | -16.0 | · | |
| P / FCF | -16.0 | · | |
| Earnings Yield | -14.1% | · |
损益表 12
| 指标 | 趋势 | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| R&D Expense | $15M | $8M | $2M | $3M | $376.0K | |
| SG&A Expense | $7M | $5M | $3M | $3M | $5M | |
| Operating Expenses | $22M | $14M | $5M | $6M | $6M | |
| Interest Income | $3M | $3M | $707.0K | $236.0K | $298.0K | |
| Other Non-op | $3M | $2M | $2M | $1M | $469.0K | |
| Pretax Income | $-19M | $-11M | $-4M | $-5M | $-5M | |
| Income Tax | $0 | $1.0K | $0 | $0 | $1.0K | |
| Net Income | $-19M | $-11M | $-4M | $-5M | $-5M | |
| EPS (Basic) | $-0.67 | $3.13 | $-0.61 | $-14.79 | $-14.00 | |
| EPS (Diluted) | $-0.67 | $3.13 | $-0.61 | $-14.79 | $-14.00 | |
| Shares (Basic) | 28,241,701 | 5,849,946 | 5,806,862 | 358,777 | 338 | |
| Shares (Diluted) | 28,241,701 | 5,849,946 | 5,806,862 | 358,777 | 338 |
资产负债表 19
| 指标 | 趋势 | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $321M | $250M | $270M | · | $23M | |
| Short-term Investments | $45M | $45M | $45M | · | $5M | |
| Prepaid Expense | $23M | $13M | $2M | · | $880.0K | |
| Current Assets | $389M | $308M | $316M | · | $29M | |
| PP&E (Net) | $2M | $2M | $2M | · | $2M | |
| PP&E (Gross) | $2M | $2M | $2M | · | $2M | |
| Accum. Depreciation | $502.0K | $420.0K | $337.0K | · | $101.0K | |
| Total Assets | $393M | $313M | $321M | · | $34M | |
| Accounts Payable | $7M | $2M | $3M | · | $2M | |
| Accrued Liabilities | $3M | $5M | $3M | · | $5M | |
| Current Liabilities | $11M | $7M | $7M | · | $8M | |
| Capital Leases | $3M | $3M | $3M | · | $3M | |
| Total Liabilities | $15M | $12M | $11M | · | $14M | |
| Common Stock | $3.0K | $3.0K | $3.0K | · | $1.0K | |
| Retained Earnings | $-149M | $-130M | $-118M | · | $-104M | |
| AOCI | $208.0K | $168.0K | $-53.0K | · | $111.0K | |
| Stockholders' Equity | $379M | $301M | $310M | · | $-95M | |
| Liabilities + Equity | $393M | $313M | $321M | · | $34M | |
| Shares Outstanding | 28,674,827 | 25,299,372 | 25,299,102 | · | 251,655 |
现金流 7
| 指标 | 趋势 | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $2M | · | $634.0K | $2M | |
| Operating Cash Flow | $-23M | $-18M | · | $-8M | $-6M | |
| CapEx | $32.0K | $40.0K | · | $21.0K | $238.0K | |
| Investing Cash Flow | $-32.0K | $-40.0K | · | $5M | $14M | |
| Financing Cash Flow | $94M | $-1M | · | $0 | $0 | |
| Net Change in Cash | $71M | $-19M | · | $-3M | $8M | |
| Free Cash Flow | $-23M | · | · | · | · |
盈利能力 2
| 指标 | 趋势 | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| ROA | -9.7% | · | -2.2% | · | · | |
| ROE | -10.1% | · | -2.3% | · | · |
流动性与偿付能力 2
| 指标 | 趋势 | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Current Ratio | 35.7 | · | 47.6 | · | · | |
| Quick Ratio | 33.5 | · | 47.3 | · | · |
估值 (TTM) 6
| 指标 | 趋势 | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Net Income TTM | $-33M | · | $-28M | · | · | |
| Market Cap | $707M | · | $399M | · | · | |
| P/B | 1.9 | · | 1.3 | · | · | |
| P / Tangible Book | 1.9 | · | 1.3 | · | · | |
| P / Cash Flow | -30.4 | · | · | · | · | |
| P / FCF | -30.3 | · | · | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| 净收入 | $-25M | $-63M |
| 稀释后每股收益 (EPS) | $-3.13 | $-176.15 |
资产负债表
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| 流动比率 | 41.4 | — |
| 速动比率 | 39.7 | — |
现金流
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| 自由现金流 | $-35M | — |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。